<code id='C3941318F6'></code><style id='C3941318F6'></style>
    • <acronym id='C3941318F6'></acronym>
      <center id='C3941318F6'><center id='C3941318F6'><tfoot id='C3941318F6'></tfoot></center><abbr id='C3941318F6'><dir id='C3941318F6'><tfoot id='C3941318F6'></tfoot><noframes id='C3941318F6'>

    • <optgroup id='C3941318F6'><strike id='C3941318F6'><sup id='C3941318F6'></sup></strike><code id='C3941318F6'></code></optgroup>
        1. <b id='C3941318F6'><label id='C3941318F6'><select id='C3941318F6'><dt id='C3941318F6'><span id='C3941318F6'></span></dt></select></label></b><u id='C3941318F6'></u>
          <i id='C3941318F6'><strike id='C3941318F6'><tt id='C3941318F6'><pre id='C3941318F6'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:explore    Page View:7
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In